Oncolytics Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. 

CEO
Jared Kelly
CEOJared Kelly
Employees
29
Employees29
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
29
Employees29

ONCY Key Statistics

Market cap
107.34M
Market cap107.34M
Price-Earnings ratio
-3.09
Price-Earnings ratio-3.09
Dividend yield
Dividend yield
Average volume
707.55K
Average volume707.55K
High today
$0.85
High today$0.85
Low today
$0.80
Low today$0.80
Open price
$0.80
Open price$0.80
Volume
544.36K
Volume544.36K
52 Week high
$1.51
52 Week high$1.51
52 Week low
$0.7301
52 Week low$0.7301

Stock Snapshot

With a market cap of 107.34M, Oncolytics Biotech(ONCY) trades at $0.83. The stock has a price-to-earnings ratio of -3.09.

During the trading session on 2026-08-22, Oncolytics Biotech(ONCY) shares reached a daily high of $0.85 and a low of $0.80. At a current price of $0.83, the stock is +3.7% higher than the low and still -2.4% under the high.

Trading volume for Oncolytics Biotech(ONCY) stock has reached 544.36K, versus its average volume of 707.55K.

Over the past 52 weeks, Oncolytics Biotech(ONCY) stock has traded between a high of $1.51 and a low of $0.73.

Over the past 52 weeks, Oncolytics Biotech(ONCY) stock has traded between a high of $1.51 and a low of $0.73.

ONCY News

Investing.com 3d
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com

...

H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com
TipRanks 3d
Oncolytics price target lowered to $5 from $10 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Oncolytics (ONCY) to $5 from $10 and keeps a Buy rating on the shares. The firm upda...

Simply Wall St 3d
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials

Advertisement Key Points Oncolytics Biotech has received written FDA feedback on the potential pivotal Part B expansion of its ongoing REO 033 colorectal canc...

Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

More ONCY News

TipRanks 4d
Oncolytics Biotech gains FDA alignment on REO 033 trial

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.